·250·中华眼科杂志2023年4月第59卷第4期Chin J0 phthalmol,April2023,Val.59,Na.4·标准与规范探讨·中国药源性角膜病变诊断和治疗专家共识(2023年)中华医学会眼科学分会角膜病学组通信作者：史伟云，山东第一医科大学附属眼科研究所山东第一医科大学附属眼科医院（山东省眼科医院）山东省眼科学重点实验室省部共建国家重点实验室培育基地山东第一医科大学眼科学院，济南250021，Email:wyshi(@sdfmu.edu.cn【摘要】药源性角膜病变主要是指药物尤其眼用药物制剂中药物本身及所含防腐剂的毒性，直接或间接导致角膜组织发生病理改变的疾病。由于其临床表现多样，缺乏特异性诊断标准，易造成误诊误治。中华医学会眼科学分会角膜病学组汇集相关领域专家，对药源性角膜病变诊治的关键技术进行梳理，形成共识性意见，以指导临床正确开展药源性角膜病变的防治工作。【关键词】角膜疾病；药物相关性副作用和不良反应；眼药水；防腐剂，药物：诊疗准则(主题)基金项目：国家自然科学基金(82271052、U20A20386):山东省重点研发计划(2022CXGC010505);山东省泰山学者青年专家计划(sqm201909188)Chinese expert consensus on the diagnosis and treatment of drug-induced keratopathy(2023)Cornea Group of Ophthalmology Branch of Chinese Medical AssociationCorresponding author:Shi Weiyun,Eye Institute of Shandong First Medical University,Eye Hospital ofShandong First Medical University (Shandong Eye Hospital),State Key Laboratory Cultivation Base,Shandong Provincial Key Laboratory of Ophthalmology,School of Ophthalmology,Shandong FirstMedical University,Jinan 250021,China,Email:wyshi@sdfmu.edu.cnAbstract Drug-induced keratopathy occurs when the use of certain drugs,particularlyophthalmic preparations,causes pathological changes in the cornea.These changes can be related tothe toxic effects of the drugs themselves or drug preservatives.The disease is characterized by arange of clinical features and lacks specific diagnostic criteria,which can lead to misdiagnosis andinappropriate treatment.In order to address these challenges,the Cornea Group of theOphthalmology Branch of the Chinese Medical Association has brought together leading experts inthe field to review key techniques for the diagnosis and treatment of drug-induced keratopathy.As aresult,they have developed this consensus to guide the prevention and treatment of this condition.Key words Corneal diseases;Drug-related side effects and adverse reactions;Ophthalmic solutions;Preservatives,pharmaceutical;Practice guidelines as topicFund program:National Natural Science Foundation of China (82271052,U20A20386);Shandong Provincial Key Research and Development Program (2022CXGC010505);Young TaishanScholars (tsqn201909188)由于药源性角膜病变临床表现多样，且患者原诊误治，病变迁延不愈，临床眼科医师应给予高度发病情各异，故缺乏特异性诊断标准，常常导致误重视。中华医学会眼科学分会角膜病学组组织全D0L:10.3760/cmaj.cm112142-20220829-00418收稿日期2022-08-29本文编辑黄翊彬引用本文：中华医学会眼科学分会角膜病学组.中国药源性角膜病变诊断和治疗专家共识(2023年)[中华眼科杂志，2023,594)：250-255.D01:10.3760/ma-j.cnl12142-20220829-00418.
